ImageneBio vs Scholar Rock
IMA and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMA and SRRK compare
Scholar Rock is the larger company, worth 134 times as much as ImageneBio ($5.3B against $39.4M).
ImageneBio scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMA | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $39.4M | $5.3B |
| Share price | $3.47 | $43.20 |
| Change, 1 year | −59.4% | 40.2% |
| Change, 5 years | −98.1% | 46.3% |
| Beta (5Y) | 1.16 | 1.50 |
| Employees | 15 | 289 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 9231× |
| P/B | 0.3× (better) | 31.2× |
| FCF yield | – | −5.9% |
| Growth | ||
| Revenue growth, 5Y average | −38.6% | – |
| Profitability | ||
| Operating margin | – | −71732% |
| Net margin | – | −72563% |
| FCF margin | – | −54371% |
| Return on equity | −32.3% (better) | −200% |
| Financial health | ||
| Debt / equity | 0.00 | 1.16 (better) |
| Interest coverage | – | −29.2× |
| Current ratio | 16.17 (better) | 5.41 |
| Altman Z-score | −1.10 | 4.22 (better) |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −3.1% |
| Shareholder yield | 0.00% (better) | −3.1% |
| Ownership | ||
| Held by institutions | 54.9% | 114% |
| Held by insiders | 52.9% | 28.9% |
| Insider net buying, 12 months | $78.5K (better) | −$7.4M |
| Short interest, % of float | 0.86% | 27.1% |
Go deeper
- IMA stock overview
- IMA income statement
- IMA valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.